Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01290887
Registration number
NCT01290887
Ethics application status
Date submitted
4/02/2011
Date registered
7/02/2011
Date last updated
6/06/2016
Titles & IDs
Public title
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Query!
Scientific title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma
Query!
Secondary ID [1]
0
0
2010-024540-15
Query!
Secondary ID [2]
0
0
C38072/3085
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Eosinophilic Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Reslizumab
Experimental: Reslizumab 3.0 mg/kg - Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
Treatment: Drugs: Reslizumab
Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [1]
0
0
An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Query!
Timepoint [1]
0
0
Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.
Query!
Primary outcome [2]
0
0
Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values
Query!
Assessment method [2]
0
0
Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values on any of the during treatment lab analyses.
Significance criteria:
* Blood urea nitrogen: \>=10.71 mmol/L
* Creatinine: \>=177 µmol/L
* Uric acid: M\>=625, F\>=506 µmol/L
* Aspartate aminotransferase: \>=3\*upper limit of normal (ULN). Normal range is 10-43 U/L
* Alanine aminotransferase: \>=3\*ULN. Normal range is 10-40 U/L
* GGT = gamma-glutamyl transpeptidase: \>= 3\*upper limit of normal. Normal range is 5-49 U/L.
* Total bilirubin: \>=34.2 µmol/L
* White blood cells- low: \<=3.0\*10\^9/L
* White blood cells-high: \>=20\*10\^9/L
* Hemoglobin: M\<=115, F\<=95 g/dL
* Hematocrit: M\<0.37, F\<0.32 L/L
* Platelets: \>=700\*10\^9/L
* Absolute neutrophil count: \<=1.0\*10\^9/L
* Eosinophils: \>=10
* Urinalysis: ketones, blood, glucose, and total protein: \>=2 unit increase from baseline
Query!
Timepoint [2]
0
0
Weeks 4, 8, 24 and 48
Query!
Primary outcome [3]
0
0
Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values
Query!
Assessment method [3]
0
0
Data represents participants with PCS vital sign values during any of the during treatment visits or the follow-up visit.
Significance criteria
* Sitting heart rate-high: \>100 and increase of \>= 30 beats/min (all ages)
* Sitting heart rate-low: \<50 and decrease of \>=30 beats/min
* Sitting systolic blood pressure (BP)-high: \>130 and increase of \>=30 mmHg (ages 12-17)
* Systolic BP-low: \<90 and decrease of \>=30 mmHg (ages \>=18)
* Systolic BP-high: \>160 and increase of \>=30 mmHg (ages \>=18)
* Sitting diastolic BP-low: \<55 and decrease of \>=12 mmHg (ages 12-17)
* Diastolic BP-high: \>85 and increase of \>=12 mmHg (ages 12-17)
* Diastolic BP-low: \<50 and decrease of \>=12 mmHg (ages \>=18)
* Diastolic BP-high: \>100 and increase of \>=12 mmHg (ages \>=18)
* Respiration rate: \>20 and increase of \>=10 breaths/minute (ages 12-17)
* Respiration rate: \>24 and increase of \>=10 breaths/minute (ages \>=18)
* Body temperature-low: \<96.5° Fahrenheit (all ages)
* Body temp-high: \>100.5° F (all ages)
Query!
Timepoint [3]
0
0
Week 4 to Week 65
Query!
Secondary outcome [1]
0
0
Forced Expiratory Volume In 1 Second (FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [1]
0
0
FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.
Query!
Timepoint [1]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [2]
0
0
Percent Predicted Forced Expiratory Volume In 1 Second (% Predicted FEV1) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [2]
0
0
The percent predicted FEV1 is the ratio of the volume of air expired in the first second of a forced expiration to the patient's predicted FEV based on a similar population without asthma. Percent predicted lung function values were transcribed directly from the lung function report to the CRF, without any calculation by Teva.
Query!
Timepoint [2]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [3]
0
0
Forced Vital Capacity (FVC) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [3]
0
0
The FVC is the volume of air that can be forcibly blown out after full inspiration, measured in liters.
.
Query!
Timepoint [3]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [4]
0
0
Forced Expiratory Flow at 25% to 75% Forced Vital Capacity (FEF 25%-75%) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [4]
0
0
The FEF 25%-75% is the force expiratory flow at 25% to 75% of the Forced Vital Capacity (FVC), measured in liters/second
.
Query!
Timepoint [4]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [5]
0
0
Average Daily Use of Short-Acting Beta-Agonist (SABA)Therapy at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [5]
0
0
SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit participants were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.
.
Query!
Timepoint [5]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [6]
0
0
Asthma Symptom Utility Index (ASUI) Score at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [6]
0
0
The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control.
.
Query!
Timepoint [6]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [7]
0
0
Asthma Control Questionnaire (ACQ) at Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, End of Study and Endpoint
Query!
Assessment method [7]
0
0
The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control.
Query!
Timepoint [7]
0
0
Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, end of study and endpoint
Query!
Secondary outcome [8]
0
0
Asthma Quality of Life Questionnaire (AQLQ) Total Score at Weeks 24, 48, 72, 96, End of Study and Endpoint
Query!
Assessment method [8]
0
0
The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were "patient-specific," which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.
Query!
Timepoint [8]
0
0
Weeks 24, 48, 72, 96, End of Study and Endpoint
Query!
Secondary outcome [9]
0
0
Participants With a Positive Anti-Reslizumab Antibody Status at Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall
Query!
Assessment method [9]
0
0
Blood samples were collected for the determination of anti-drug antibody (ADAs) before study drug infusion at baseline and every 24 weeks until end of treatment visit or early withdrawal. Serum samples were analyzed by Teva (Teva Biopharmaceuticals USA, Rockville, Maryland, USA) using a validated homogeneous solution based bridging enzyme linked immune sorbent assay (Mikulsis et al 2011, Qui et al 2010). The analysis of anti-reslizumab antibody in patient serum consists of 3 tiers of assays for screening, confirmation, and titer analysis. If a participant had a treatment-emergent ADA response (ie, ADA positive at any of the postdose time points but negative at the predose time point) or if there was a treatment-boosted ADA response (defined as a greater than 4-fold increase from a positive baseline ADA response (Shankar et at 2014), the participant was classified as overall ADA positive.
Predose samples for the reslizumab-experienced participants came from the previous studies.
Query!
Timepoint [9]
0
0
Baseline, Weeks 24, 48, 72, 96, End of Study, Endpoint and Overall
Query!
Eligibility
Key inclusion criteria
* Written informed consent is obtained.
* Patient must have completed treatment in a previous Cephalon-sponsored double-blind asthma exacerbation study or received at least 2 doses of study drug treatment in a pulmonary function study.
* The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.
* other criteria may apply; please contact the investigator for more information.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.
* The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer).
* The patient is a current smoker.
* The patient is expected to be poorly compliant with study drug administration, study procedures, or visits.
* The patient has any aggravating factors that are inadequately controlled (e.g., gastroesophageal reflux disease [GERD]).
* Female patients who are pregnant, or nursing, or, if of childbearing potential and not using a medically accepted, effective method of birth control (eg, spermicide, abstinence, intrauterine device [IUD], or steroidal contraceptive [oral, transdermal, implanted, and injected] in conjunction with a barrier method) are excluded from this study.
* The patient has a current infection or disease that may preclude assessment of asthma.
* other criteria may apply; please contact the investigator for more information.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1052
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Teva Investigational Site 641 - East Bentleigh
Query!
Recruitment hospital [2]
0
0
Teva Investigational Site 642 - Frankston
Query!
Recruitment hospital [3]
0
0
Teva Investigational Site 645 - Liverpool
Query!
Recruitment hospital [4]
0
0
Teva Investigational Site 643 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- East Bentleigh
Query!
Recruitment postcode(s) [2]
0
0
- Frankston
Query!
Recruitment postcode(s) [3]
0
0
- Liverpool
Query!
Recruitment postcode(s) [4]
0
0
- Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maine
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Rhode Island
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Ciudad Autonoma de Buenos Aire
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Quilmes-Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Rosario-Santa Fe
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Rosario
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
San Miguel de Tucuman - Tucuma
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Bruxelles
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Gent
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Jambes
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liège
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Belo Horizonte
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Florianopolis
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Porto Alegre - RS
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Porto Alegre, RS
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Porto Alegre
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Santo André, São Paulo
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Calgary
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Montreal
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Newmarket
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Windsor
Query!
Country [41]
0
0
Chile
Query!
State/province [41]
0
0
Rancagua
Query!
Country [42]
0
0
Chile
Query!
State/province [42]
0
0
Santiago
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Temuco
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Valdivia
Query!
Country [45]
0
0
Chile
Query!
State/province [45]
0
0
Valparaiso
Query!
Country [46]
0
0
Colombia
Query!
State/province [46]
0
0
Bogota
Query!
Country [47]
0
0
Colombia
Query!
State/province [47]
0
0
Bogotá
Query!
Country [48]
0
0
Colombia
Query!
State/province [48]
0
0
Cali
Query!
Country [49]
0
0
Colombia
Query!
State/province [49]
0
0
Floridablanca
Query!
Country [50]
0
0
Czech Republic
Query!
State/province [50]
0
0
Breclav
Query!
Country [51]
0
0
Czech Republic
Query!
State/province [51]
0
0
Brno
Query!
Country [52]
0
0
Czech Republic
Query!
State/province [52]
0
0
Liberec
Query!
Country [53]
0
0
Czech Republic
Query!
State/province [53]
0
0
Olomouc
Query!
Country [54]
0
0
Czech Republic
Query!
State/province [54]
0
0
Tabor
Query!
Country [55]
0
0
Denmark
Query!
State/province [55]
0
0
Odense
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Marseille
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Montpellier
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Berlin
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Bochum
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Frankfurt
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Hamburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Koblenz
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Leipzig
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Mainz
Query!
Country [65]
0
0
Greece
Query!
State/province [65]
0
0
Athens
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Balassagyarmat
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Miskolc
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Mosonmagyaróvár
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Sopron
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Szazhalombatta
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Tatabánya
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Törökbálint
Query!
Country [73]
0
0
Israel
Query!
State/province [73]
0
0
Ashkelon
Query!
Country [74]
0
0
Israel
Query!
State/province [74]
0
0
Haifa
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Jerusalem
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Kfar Saba
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Petach Tikva
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Ramat Gan
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Rehovot
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Tel-Aviv
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Gwangju
Query!
Country [82]
0
0
Korea, Republic of
Query!
State/province [82]
0
0
Seoul
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Suwon
Query!
Country [84]
0
0
Malaysia
Query!
State/province [84]
0
0
Batu Caves
Query!
Country [85]
0
0
Malaysia
Query!
State/province [85]
0
0
Kuala Lumpur
Query!
Country [86]
0
0
Malaysia
Query!
State/province [86]
0
0
Penang
Query!
Country [87]
0
0
Malaysia
Query!
State/province [87]
0
0
Taiping
Query!
Country [88]
0
0
Mexico
Query!
State/province [88]
0
0
Ciudad De México
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Distrito Federal
Query!
Country [90]
0
0
Mexico
Query!
State/province [90]
0
0
Guadalajara, JAL
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Hermosillo, Sonora
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Mexico City
Query!
Country [93]
0
0
Mexico
Query!
State/province [93]
0
0
Monterrey
Query!
Country [94]
0
0
Mexico
Query!
State/province [94]
0
0
Tijuana, B.C.
Query!
Country [95]
0
0
Netherlands
Query!
State/province [95]
0
0
Heerlen
Query!
Country [96]
0
0
New Zealand
Query!
State/province [96]
0
0
Auckland
Query!
Country [97]
0
0
New Zealand
Query!
State/province [97]
0
0
Dunedin
Query!
Country [98]
0
0
New Zealand
Query!
State/province [98]
0
0
Hamilton
Query!
Country [99]
0
0
New Zealand
Query!
State/province [99]
0
0
Tauranga
Query!
Country [100]
0
0
New Zealand
Query!
State/province [100]
0
0
Wellington
Query!
Country [101]
0
0
Peru
Query!
State/province [101]
0
0
Cercado de Lima, Lima
Query!
Country [102]
0
0
Peru
Query!
State/province [102]
0
0
Lima
Query!
Country [103]
0
0
Philippines
Query!
State/province [103]
0
0
Manila
Query!
Country [104]
0
0
Philippines
Query!
State/province [104]
0
0
Quezon City
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Bialystok
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Bydgoszcz
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Gdansk
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Lodz
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Lublin
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Ostrow Wielkopolski
Query!
Country [111]
0
0
Poland
Query!
State/province [111]
0
0
Poznan
Query!
Country [112]
0
0
Poland
Query!
State/province [112]
0
0
Tarnow
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Bucharest
Query!
Country [114]
0
0
Romania
Query!
State/province [114]
0
0
Cluj-Napoca
Query!
Country [115]
0
0
Romania
Query!
State/province [115]
0
0
Iasi
Query!
Country [116]
0
0
Romania
Query!
State/province [116]
0
0
Targu Mures
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Barnaul
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Kemerovo
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Moscow
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Novosibirsk
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
St. Petersburg
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
St.Petersburg
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Tomsk
Query!
Country [124]
0
0
Russian Federation
Query!
State/province [124]
0
0
Yaroslavl
Query!
Country [125]
0
0
Slovakia
Query!
State/province [125]
0
0
Bradejov
Query!
Country [126]
0
0
Slovakia
Query!
State/province [126]
0
0
Levice
Query!
Country [127]
0
0
Slovakia
Query!
State/province [127]
0
0
Spisska Nova Ves
Query!
Country [128]
0
0
Slovakia
Query!
State/province [128]
0
0
Topolcany
Query!
Country [129]
0
0
South Africa
Query!
State/province [129]
0
0
Cape Town
Query!
Country [130]
0
0
South Africa
Query!
State/province [130]
0
0
Centurion
Query!
Country [131]
0
0
South Africa
Query!
State/province [131]
0
0
Durban
Query!
Country [132]
0
0
South Africa
Query!
State/province [132]
0
0
Johannesburg
Query!
Country [133]
0
0
South Africa
Query!
State/province [133]
0
0
Pretoria
Query!
Country [134]
0
0
Sweden
Query!
State/province [134]
0
0
Göteborg
Query!
Country [135]
0
0
Sweden
Query!
State/province [135]
0
0
Linköping
Query!
Country [136]
0
0
Sweden
Query!
State/province [136]
0
0
Lund
Query!
Country [137]
0
0
Sweden
Query!
State/province [137]
0
0
Malmö
Query!
Country [138]
0
0
Taiwan
Query!
State/province [138]
0
0
Taipei
Query!
Country [139]
0
0
Taiwan
Query!
State/province [139]
0
0
Taoyuan
Query!
Country [140]
0
0
Thailand
Query!
State/province [140]
0
0
Bangkok
Query!
Country [141]
0
0
Thailand
Query!
State/province [141]
0
0
Nakhon Ratchasima
Query!
Country [142]
0
0
Ukraine
Query!
State/province [142]
0
0
Dnipropetrovsk
Query!
Country [143]
0
0
Ukraine
Query!
State/province [143]
0
0
Donetsk
Query!
Country [144]
0
0
Ukraine
Query!
State/province [144]
0
0
Ivano-Frankivsk
Query!
Country [145]
0
0
Ukraine
Query!
State/province [145]
0
0
Kharkiv
Query!
Country [146]
0
0
Ukraine
Query!
State/province [146]
0
0
Kyiv
Query!
Country [147]
0
0
Ukraine
Query!
State/province [147]
0
0
Vinnytsya
Query!
Country [148]
0
0
Ukraine
Query!
State/province [148]
0
0
Zaporizhzhia
Query!
Country [149]
0
0
Ukraine
Query!
State/province [149]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Teva Branded Pharmaceutical Products R&D, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by adverse events, physical examination findings, vital sign measurements, and concomitant medication usage throughout the study (every 4 weeks), clinical laboratory test results, and measurement of antidrug antibodies.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01290887
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Sponsor's Medical Expert, Senior Director - Worldwide Clinical Research
Query!
Address
0
0
Cephalon
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01290887
Download to PDF